Cargando…

Immune Checkpoint Receptors Tim-3 and PD-1 Regulate Monocyte and T Lymphocyte Function in Septic Patients

We aim to investigate the effects of Tim-3 and programmed cell death-1 (PD-1) on the monocytes and T lymphocytes in septic patients. Expression of Tim-3 and PD-1 on the CD3, CD4, and CD8 lymphocytes and monocytes was determined using flow cytometry. CBA technique was utilized to determine the expres...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xia, Qi, Wei, Li, Zhang, Yuntao, Sheng, Jifang, Wu, Wei, Zhang, Yi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282152/ https://www.ncbi.nlm.nih.gov/pubmed/30595665 http://dx.doi.org/10.1155/2018/1632902

Ejemplares similares

Association of Lymphocyte-to-Monocyte Ratio With Survival in Advanced Gastric Cancer Patients Treated With Immune Checkpoint Inhibitor
por: Chen, Yang, et al.
Publicado: (2021)

High co-expression of immune checkpoint receptors PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT on tumor-infiltrating lymphocytes in early-stage breast cancer
por: Mollavelioglu, Baran, et al.
Publicado: (2022)

Immune Checkpoint Profiling in Humanized Breast Cancer Mice Revealed Cell-Specific LAG-3/PD-1/TIM-3 Co-Expression and Elevated PD-1/TIM-3 Secretion
por: Bruss, Christina, et al.
Publicado: (2023)

Differences in Immune Checkpoints Expression (TIM-3 and PD-1) on T Cells in Women with Recurrent Miscarriages—Preliminary Studies
por: Zych, Michał, et al.
Publicado: (2021)

The immune checkpoint molecules PD-1, PD-L1, TIM-3 and LAG-3 in diffuse large B-cell lymphoma
por: Chen, Benjamin J., et al.
Publicado: (2019)

The Role of the Immune Checkpoint Molecules PD-1/PD-L1 and TIM-3/Gal-9 in the Pathogenesis of Preeclampsia—A Narrative Review
por: Mittelberger, Johanna, et al.
Publicado: (2022)

Expression of the immune checkpoint receptors PD-1, LAG3, and TIM3 in the immune context of stage II and III gastric cancer by using single and chromogenic multiplex immunohistochemistry
por: Park, Yujun, et al.
Publicado: (2021)

Genetic polymorphisms of immune checkpoint proteins PD-1 and TIM-3 are associated with survival of patients with hepatitis B virus-related hepatocellular carcinoma
por: Li, Zhu, et al.
Publicado: (2016)

Analysis of PD-1 expression in the monocyte subsets from non-septic and septic preterm neonates
por: Zasada, Magdalena, et al.
Publicado: (2017)

TIM-3 Is a Potential Immune Checkpoint Target in Cats with Mammary Carcinoma
por: Valente, Sofia, et al.
Publicado: (2023)

Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients
por: Marcq, Elly, et al.
Publicado: (2017)

Immune regulation by Tim-3
por: Banerjee, Hridesh, et al.
Publicado: (2018)

Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4(+) T Cells
por: Saleh, Reem, et al.
Publicado: (2019)

Tim-3 Negatively Regulates IL-12 Expression by Monocytes in HCV Infection
por: Zhang, Ying, et al.
Publicado: (2011)

Immune checkpoint proteins PD-1 and TIM-3 are both highly expressed in liver tissues and correlate with their gene polymorphisms in patients with HBV-related hepatocellular carcinoma
por: Li, Zhu, et al.
Publicado: (2016)

PD-1 blockade upregulate TIM-3 expression as a compensatory regulation of immune check point receptors in HNSCC TIL
por: Shayan, Gulidanna, et al.
Publicado: (2015)

B-cell immune checkpoint TIM-1: a potential target for tumour immunotherapy
por: Tian, Xinyu, et al.
Publicado: (2023)

Elevation of Tim-3 and PD-1 Expression on T Cells Appears Early in HIV Infection, and Differential Tim-3 and PD-1 Expression Patterns Can Be Induced by Common γ-Chain Cytokines
por: Zhang, Zi-Ning, et al.
Publicado: (2015)

Prognostic Value of Lymphocyte-to-Monocyte Ratio (LMR) in Cancer Patients Undergoing Immune Checkpoint Inhibitors
por: Wan, Luying, et al.
Publicado: (2022)

Regulation of Monocyte-Macrophage Responses in Cirrhosis—Role of Innate Immune Programming and Checkpoint Receptors
por: Riva, Antonio, et al.
Publicado: (2019)

Systemic levels of the soluble co-inhibitory immune checkpoints, CTLA-4, LAG-3, PD-1/PD-L1 and TIM-3 are markedly increased in basal cell carcinoma
por: Malinga, Nonkululeko Z., et al.
Publicado: (2022)

TIMs: central regulators of immune responses
por: Hafler, David A., et al.
Publicado: (2008)

PD-1 and Tim-3 Pathways Regulate CD8(+) T Cells Function in Atherosclerosis
por: Qiu, Ming-Ke, et al.
Publicado: (2015)

Glycoproteomic landscape and structural dynamics of TIM family immune checkpoints enabled by mucinase SmE
por: Chongsaritsinsuk, Joann, et al.
Publicado: (2023)

Glycoproteomic landscape and structural dynamics of TIM family immune checkpoints enabled by mucinase SmE
por: Chongsaritsinsuk, Joann, et al.
Publicado: (2023)

Expression of Immune Checkpoint Regulators IDO, VISTA, LAG3, and TIM3 in Resected Pancreatic Ductal Adenocarcinoma
por: Popp, Felix C., et al.
Publicado: (2021)

The Roles of microRNAs in Regulating the Expression of PD-1/PD-L1 Immune Checkpoint
por: Wang, Qingshui, et al.
Publicado: (2017)

CMTM6-Deficient Monocytes in ANCA-Associated Vasculitis Fail to Present the Immune Checkpoint PD-L1
por: Zeisbrich, Markus, et al.
Publicado: (2021)

Expression of immune checkpoints (PD-L1 and IDO) and tumour-infiltrating lymphocytes in breast cancer
por: Alkhayyal, Noura, et al.
Publicado: (2022)

Immune Regulation and Antitumor Effect of TIM-1
por: Du, Peng, et al.
Publicado: (2016)

Immune Co-inhibitory Receptors CTLA-4, PD-1, TIGIT, LAG-3, and TIM-3 in Upper Tract Urothelial Carcinomas: A Large Cohort Study
por: Jin, Shengming, et al.
Publicado: (2023)

Modulation of the Gal-9/TIM-3 Immune Checkpoint with α-Lactose. Does Anomery of Lactose Matter?
por: Bailly, Christian, et al.
Publicado: (2021)

Association of TIM-3 checkpoint receptor expression on T cells with treatment-free remission in chronic myeloid leukemia
por: Irani, Yazad D., et al.
Publicado: (2023)

Targeting Tim-3 in Cancer With Resistance to PD-1/PD-L1 Blockade
por: Tian, Tian, et al.
Publicado: (2021)

TIM-3: a tumor-associated antigen beyond checkpoint inhibition?
por: Barth, Stefan, et al.
Publicado: (2022)

Upregulation of Galectin-9 and PD-L1 Immune Checkpoints Molecules in Patients with Chronic Lymphocytic Leukemia
por: Taghiloo, Saeid, et al.
Publicado: (2017)

Simultaneous and Spatially-Resolved Analysis of T-Lymphocytes, Macrophages and PD-L1 Immune Checkpoint in Rare Cancers
por: Cereceda, Karina, et al.
Publicado: (2022)

Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases
por: Harter, Patrick N., et al.
Publicado: (2015)

Down-Regulation of Tim-3 in Monocytes and Macrophages in Plasmodium Infection and Its Association with Parasite Clearance
por: Hou, Nan, et al.
Publicado: (2017)

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
por: Sakuishi, Kaori, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_41qbrt00rbt9t5affocbe874l0